Gilles de la Tourette's syndrome prodrug therapeutic - KemPharm

Drug Profile

Gilles de la Tourette's syndrome prodrug therapeutic - KemPharm

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KemPharm
  • Class Antiparkinsonians; Neuropsychotherapeutics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Gilles de la Tourette's syndrome

Most Recent Events

  • 04 Oct 2017 KemPharm in-licenses nano-particulate amphetamine technology from Genco Sciences
  • 04 Oct 2017 Early research in Gilles de la Tourette's syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top